Major Depressive Disorder

A trend shows there is an association between the rise of LSD and adults with depression—but it is even more prevalent in young adults aged 18-34 than older adults.

Only roughly 21% of adolescents with mental health issues receive outpatient treatment, according to a new study.

Extended-release quetiapine is commonly used for treatment-resistant depression, but a new study reveals patients receiving esketamine nasal spray are 54% more likely to reach remission at 8 weeks.

Investigators of a new meta-analysis designed the Psymatik Treatment Optimizer, an online tool which synthesizes side-effects in a database and can personalize individual user side effect concerns.

Multiple cohorts of health care professions, including registered nurses and social/behavioral workers, are at greater risk of suicide than the general population, according to new data.

Investigators believe their findings may help reduce the negative of self-stigma and subjective symptom reporting burdening patients with depression.

The indication is the first for an antidepressant that selectively targets the serotonin 1A receptor—a regulator of mood and emotion.

New data from Sweden conflict with previous register-based research showing a “substantially” increased risk of mania among antidepressant-treated pediatric patients with unipolar depression.

Geoffrey Grammer, MD, offers guidance on navigating challenges such as elevated blood pressure and substance misuse and abuse regarding the use of esketamine.

Hanita Chhabra, MD, highlights safety and efficacy data of esketamine and shares practical implications for clinical practice.

William M. Sauve, MD, reviews the landscape of delivery mechanisms for ketamine agents, including intravenous, sublingual, and intramuscular.

Steve Harvey, MD, discusses the challenges of defining treatment resistant depression and provides and overview of treatment options.

New phase 2 data adds to the growing interest in the psychedelic treatment as a novel drug to treat MDD.

A prospective cohort analysis of pregnant women in Rotterdam shows a potential link between the popular drug class and emotional regulation development trajectories.

A study of 7 million-plus US adults shows telehealth visits for mental health conditions increased more than 10-fold during the COVID-19 pandemic.

A large systematic review assessing more than 60 drugs for bipolar depression shows only a handful were statistically signifcantly better than placebo per depressive symptom outcomes.

A proof-of-concept trial shows a program that addresses sleep pressure, circadian rhythm and hyperarousal in adolescents and young adults receiving mental health care is promising.

New cohort analysis shows residents entering medicine in 2020 were actually less likely to report symptoms of PTSD than their earlier peers.

The pioneer in social anxiety disorder discusses how the investigative nasal spay may alter the trajectory of patients' conditions.

Instances of urgent IBD hospitalization, surgery, death or lack of response to steroid therapy are linked to symptoms of depression and anxiety.

Vistagen reported significant improvement of physician- and patient-reported anxiety among trial participants who underwent an anxiety-inducing public speaking exercise.

The approval marks the first indication for a postpartum depression drug—one that which has been touted for its rapid-acting effect and sustained benefits.

The results found those with sexual minority status were significantly more likely to attend prenatal care visits (20%) when compared with heterosexual women.